Herombopag for low platelets from chemotherapy side effects
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 2 trial studies herombopag to raise very low platelet counts caused by chemotherapy and reduce bleeding risk. It may help people whose platelet levels stay too low even after prior standard attempts like rhTPO or IL-11.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older and able to follow study visits and procedures
- Have chemotherapy-induced low platelets (CIT) that did not improve after repeated treatment with rhTPO or IL-11
- Stop chemotherapy or radiotherapy for more than 1 month, and have platelet counts under 30 with a bleeding tendency
- Have enough health to stay in the study: liver and kidney tests must be below 1.5 times the normal limit, and expected survival is at least 6 months
- Not be pregnant or breastfeeding, and be willing to use reliable birth control during the study (with a negative pregnancy test for women)
- Most important to avoid: serious uncontrolled organ disease, life-threatening bleeding in the brain/lungs/upper stomach, major clotting conditions, and positive blood tests for HIV or hepatitis B/C/D or certain virus DNA tests
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests eltrombopag to help people with low platelet counts caused by chemotherapy (which can increase bleeding risk). It looks at whether raising platelets can reduce bleeding problems and help you stay on track with care.
This trial tests a medication called Herombopag to raise platelet counts in adults aged 60 or older with immune thrombocytopenia (ITP). The goal is to see if it is safe and effective for this age group.
This trial tests a drug called romiplostim for patients whose platelet counts stay very low (below 30) for a long time after chemotherapy, even after other treatments have failed. The goal is to see if romiplostim can help raise your platelet count to a safer level.
This Phase 2 study tests hetrombopag to treat chemotherapy-related low platelet counts in adults with acute myeloid leukemia (AML) in remission. It aims to help keep platelets up so you can safely continue chemotherapy.
This trial tests a drug called hetrombopag to help raise platelet counts in women whose cancer therapy has caused low platelets. The goal is to see if it can safely prevent the need for platelet transfusions.
This trial tests a pill called herombopag to prevent low platelets caused by chemo and radiation for cervical cancer. The goal is to see if it can help keep your platelet levels safe so you can complete your treatment.
Hear when a new Chemotherapy Induced Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.